Evidence map›Paper›PMID 42881344›Full record

ArticlePharmaceutical research2026

Long-lasting Inhibition of L-type Amino Acid Transporter 1 by Nanvuranlat is Associated with Prolonged Cellular Retention Counteracted by Cancer-type OATP1B3 in Cholangiocarcinoma Cells.

Kiyoshi Oka, Yusuke Masuo, Atsunosuke Yamada, Tokiko Suzuki, Kazuo Sekiguchi, Masuhiro Yoshitake, Yukio Kato

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kiyoshi OkaFaculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.
Yusuke MasuoFaculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.
Atsunosuke YamadaFaculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.
Tokiko SuzukiJ-Pharma Co., Ltd., 1-10-11 Hamamatsucho, Minato-ku, Tokyo, 105-0013, Japan.
Kazuo SekiguchiJ-Pharma Co., Ltd., 1-10-11 Hamamatsucho, Minato-ku, Tokyo, 105-0013, Japan.
Masuhiro YoshitakeJ-Pharma Co., Ltd., 1-10-11 Hamamatsucho, Minato-ku, Tokyo, 105-0013, Japan.
Yukio KatoFaculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan. ykato@p.kanazawa-u.ac.jp.ORCID http://orcid.org/0000-0001-8135-5679

Funding

JSPS KAKENHI Grants-in-Aid for Scientific Research (B) 22H02781JST SPRING JPMJSP2135
6 · The paper itself

Abstract

purposeNanvuranlat (JPH203, NVL) is a selective L-type amino acid transporter 1 (LAT1) inhibitor that shows antitumor activity despite rapidly declining blood concentrations. This study investigated whether its long-lasting inhibition of LAT1 is associated with its cellular retention in HuCCT-1 cells, a human cholangiocarcinoma cell line.

methodsAfter NVL exposure and washout, LAT1 activity was evaluated by [

resultsFollowing preincubation with 100 µM NVL and a 4-h washout, [

conclusionsProlonged cellular retention of NVL contributes to long-lasting LAT1 inhibition in HuCCT-1 cells. Tumor retention of NVL may partly explain the discrepancy between plasma exposure and antitumor efficacy. Ct-OATP1B3 may modulate NVL retention and sustained pharmacological activity in HuCCT-1 cells.

Indexed as

cancer-type OATP1B3cellular retentionHuCCT-1 cellsL-type amino acid transporter 1nanvuranlat

Identifiers

PMID42881344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.